VENLO, the Netherlands / Jan 15, 2025 / Business Wire / QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter 2024.
Press release date / time: Wednesday, February 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Thursday, February 6, at 16:00 Frankfurt time / 15:00 London time / 10:00 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 646 828 8193
UK: +44 (0)330 165 4027
GER: +49 (0)69 6610 2480
Conference ID: 9237018
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link:
https://event.webcasts.com/starthere.jsp?ei=1684130&tp_key=c56f1d6ba2
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of September 30, 2024, QIAGEN employed more than 5,800 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
| Last Trade: | US$38.89 |
| Daily Change: | -0.86 -2.16 |
| Daily Volume: | 1,067,935 |
| Market Cap: | US$8.640B |
March 06, 2025 February 13, 2025 February 05, 2025 January 12, 2025 January 10, 2025 | |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
